TI
IONS icon

tru Independence’s Ionis Pharmaceuticals IONS Stock Holding History

tru Independence’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-136
Closed -$8 – 590
2020
Q2 		$8 Buy
136
+100
+278% +$5.56K ﹤0.01% 634
2020
Q1 		$2 Hold
36
– – ﹤0.01% 630
2019
Q4 		$2K Buy
+36
New +$2.15K ﹤0.01% 803

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

tru Independence's IONS Position: Q3 2020 in Review

tru Independence sold out of Ionis Pharmaceuticals (IONS) in Q3 2020, closing a stake of 136 shares — an estimated $8 sold.

tru Independence first reported a position in IONS in Q4 2019 and held it in 3 quarters. The position peaked at $2K in Q4 2019. 367 funds tracked by Wall St. Rank hold IONS as of Q3 2020.

  • tru Independence reported no remaining Ionis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 136 Ionis Pharmaceuticals shares in Q3 2020, an estimated $8.
  • tru Independence first reported a position in Ionis Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • tru Independence's Ionis Pharmaceuticals position peaked at $2K in Q4 2019.
  • 367 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.